ABILIFY in Croatian translation

• abilify
• lijeka abilify
• lijekom abilify

Examples of using Abilify in English and their translations into Croatian

Injections of Abilify were also more effective than placebo in reducing the symptoms of agitation,
Injekcije lijeka Abilify bile su također djelotvornije od placeba u redukciji simptoma agitacije

Receiving Abilify Maintena with some medicines may mean the doctor will need to change your dose of Abilify Maintena or the other medicines.
Primanje Abilify Maintena s nekim lijekovima može značiti da će Vam liječnik morati promijeniti dozu lijeka Abilify Maintena ili tih drugih lijekova.

Concomitant administration of Abilify Maintena and other inducers of CYP3A4(such as rifampicin,
Istodobna primjena lijeka Abilify Maintena i drugih induktora CYP3A4(kao

Thus, superiority of Abilify Maintena over the aripiprazole Long-Acting Injectable 50 mg/25 mg was established
Tako je bila ustanovljena superiornost lijeka Abilify Maintena nad dugodjelujućim aripiprazolom u injekcijama od 50 mg/25 mg,

The safety and efficacy of Abilify Maintena in the treatment of schizophrenia in patients 65 years of age
Starije osobe Sigurnost i djelotvornost lijeka Abilify Maintena u liječenju shizofrenije u bolesnika u dobi od 65 godina

Similarly, there was no clinically relevant effect of gender in a population pharmacokinetic analysis of Abilify Maintena in clinical trials in patients with schizophrenia.
Slično tome, u analizi populacijske farmakokinetike lijeka Abilify Maintena u kliničkim ispitivanjima u bolesnika sa shizofrenijom nije bilo klinički važnog utjecaja spola.

The efficacy of Abilify Maintena in acutely relapsed adult patients with schizophrenia was established in a short-term(12-week),
Djelotvornost lijeka Abilify Maintena u odraslih bolesnika s akutnim relapsom shizofrenije ustanovljena je u kratkotrajnom(12 tjedana),

The efficacy of Abilify Maintena in the maintenance treatment of patients with schizophrenia was established in two randomised, double-blind, long-term trials.
Djelotvornost lijeka Abilify Maintena u terapiji održavanja u liječenju bolesnika sa shizofrenijom bila je ustanovljena u dva randomizirana dvostruko slijepa, dugotrajna ispitivanja.

The eighth study looked at the effect of adding Abilify or placebo to existing treatment with lithium
Osmo ispitivanje proučavalo je dodavanja lijeka Abilify ili placeba postojećem liječenju litijem

showed superiority of Abilify Maintena(n 167) over placebo n 172.
pokazao je superiornost lijeka Abilify Maintena(n 167) u odnosu na placebo n 172.

But I don't take them anymore, no. I used to be on lithium, and Seroquel and Abilify.
Prije sam bio na Litijumu i Seroquelu, i Abilifyju,… ali više ih ne uzimam, ne.

I used to be on lithium and Seroquel and Abilify, but I don't take them anymore.
Bio sam na Lithiumu, Seroquelu i Abilifyju, ali ih više ne uzimam.

When compared to studies where Abilify Maintena was injected in the gluteal muscle,
U usporedbi s ispitivanjima u kojima se Abilify Maintena injicirao u glutealni mišić, ponovna pojava bola

When used to treat bipolar disorder, Abilify was more effective than placebo at reducing manic symptoms in four of the five short-term studies in adults.
Kada se koristio za liječenje bipolarnog poremećaja Abilify se pokazao djelotvornijim od placeba u redukciji simptoma manije u četiri od pet kratkoročnih ispitivanja na odraslima.

Abilify is also used for up to 12 weeks to treat moderate to severe manic episodes in patients aged 13 years or over.
Abilify se također koristio do 12 tjedana za liječenje umjerenih do teških maničnih epizoda u bolesnika u dobi od 13 pa naviše.

Abilify is used in adults to treat moderate to severe manic episodes
Abilify se koristi u odraslih za liječenje umjerenih do teških maničnih epizoda

Abilify Maintena should not be used to manage acutely agitated
Abilify Maintena se ne smije koristiti za liječenje stanja akutne agitacije ili teških psihotičnih stanja

In the study in children and adolescents, Abilify was also more effective than placebo at reducing the manic symptoms of bipolar disorder.
U ispitivanju na djeci i adolescentima Abilify se također pokazao djelotvornijim od placeba u redukciji maničnih simptoma bipolarnog poremećaja.

The European Commission granted a marketing authorisation valid throughout the European Union for Abilify Maintena on 15 November 2013.
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Abilify Maintena na snazi u Europskoj uniji od 15. studenog 2013.

Therefore, the CHMP's view was that, as for Abilify, the benefit outweighs the identified risk.
Stoga je stav CHMP-a da, kao i u pogledu lijeka Abilify, koristi nadmašuju utvrđene rizike.